Carina Ribeiro Lopes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Carina Ribeiro Lopes has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Silvana Marques de Araújo
Universidade Estadual de Maringá
2 shared publications - Camila Fernanda Brustolin Aleixo
Department of Basic Health Sciences, Laboratory of Parasitology, Universidade Estadual de Maringá, Avenida Colombo, 5790, Jd. Universitário, bloco I90, sala 11, 87020-900 Maringá, Paraná, Brazil
1 shared publication Caroline Felicio Braga
Universidade Estadual de Maringá
1 shared publicationDenise Lessa Aleixo
Universidade Estadual de Maringá
1 shared publication- Denise Lessa Aleixo
Universidade Estadual de Maringá, Departamento de Ciências Básicas da Saúde/Parasitologia, Maringá, PR, Brazil
1 shared publication - Edilson Nobuyoshi Kaneshima
Universidade Estadual de Maringá
1 shared publication
Latest Publications
- Open Access
The cytoplasmic scaffolding protein PCNA regulates NLRP3 inflammasome activation in macrophages
Key components of innate immune responses, the NLRP3 sensor, ASC adaptor and Caspase-1 effector form the NLRP3 inflammasome, whose assembly leads to both inflammatory cytokines secretion and cell death. Its priming and activation are regulated by numerous proteins including the serine/threonine kinase NEK7. PCNA is a nuclear scaffolding protein essential for DNA replication. In neutrophils, which are differentiated cells deprived of proliferative capacity, PCNA is exclusively cytoplasmic and regulates neutrophil functions through interactions with different protein partners. Among them, pro-Caspases-3/8/9/10 interact with PCNA to regulate apoptosis. We therefore hypothesize that cytoplasmic PCNA could serve as a regulatory platform for the NLRP3 inflammasome via its interaction with its components. In PMA-differentiated THP-1 macrophages, PCNA relocalized mainly in the cytoplasm. Furthermore, PCNA scaffold inhibitors inhibited IL-1β secretion, pro-Caspase-1 cleavage and pyroptosis-activating gasdermin D cleavage, induced by either nigericin, monosodium urate crystals or Escherichia coli bacteria. Nigericin-stimulation resulted in cytoplasmic PCNA binding to NEK7 and potentially NLRP3, and the p21 peptide, the highest competitive inhibitor of PCNA partner binding, disrupted PCNA-NEK7 interaction. Finally, use of bone marrow-derived macrophages from p21 knockout mice suggested that the cyclin-dependent kinase inhibitor p21 might be a natural repressor of the NLRP3 inflammasome. This work provides a proof-of-principle for the potential of disrupting PCNA interactions to regulate both canonical and non-canonical NLRP3 inflammasomes.
Open AccessThe cytoplasmic scaffolding protein PCNA regulates NLRP3 inflammasome activation in macrophages
Key components of innate immune responses, the NLRP3 sensor, ASC adaptor and Caspase-1 effector form the NLRP3 inflammasome, whose assembly leads to both inflammatory cytokines secretion and cell death. Its priming and activation are regulated by numerous proteins including the serine/threonine kinase NEK7. PCNA is a nuclear scaffolding protein essential for DNA replication. In neutrophils, which are differentiated cells deprived of proliferative capacity, PCNA is exclusively cytoplasmic and regulates neutrophil functions through interactions with different protein partners. Among them, pro-Caspases-3/8/9/10 interact with PCNA to regulate apoptosis. We therefore hypothesize that cytoplasmic PCNA could serve as a regulatory platform for the NLRP3 inflammasome via its interaction with its components. In PMA-differentiated THP-1 macrophages, PCNA relocalized mainly in the cytoplasm. Furthermore, PCNA scaffold inhibitors inhibited IL-1β secretion, pro-Caspase-1 cleavage and pyroptosis-activating gasdermin D cleavage, induced by either nigericin, monosodium urate crystals or Escherichia coli bacteria. Nigericin-stimulation resulted in cytoplasmic PCNA binding to NEK7 and potentially NLRP3, and the p21 peptide, the highest competitive inhibitor of PCNA partner binding, disrupted PCNA-NEK7 interaction. Finally, use of bone marrow-derived macrophages from p21 knockout mice suggested that the cyclin-dependent kinase inhibitor p21 might be a natural repressor of the NLRP3 inflammasome. This work provides a proof-of-principle for the potential of disrupting PCNA interactions to regulate both canonical and non-canonical NLRP3 inflammasomes.
- 1 May 2016
- Published by Georg Thieme Verlag KG in Homeopathy
- Vol. 105 (2) , 186-193
Highly diluted medication reduces tissue parasitism and inflammation in mice infected by Trypanosoma cruzi
To evaluate the effects of Kalium causticum, Conium maculatum, and Lycopodium clavatum 13cH in mice infected by Trypanosoma cruzi. In a blind, controlled, randomized study, 102 male Swiss mice, 8 weeks old, were inoculated with 1400 trypomastigotes of the Y strain of T. cruzi and distributed into the following groups: CI (treated with 7% hydroalcoholic solution), Ca (treated with Kalium causticum 13cH), Co (treated with Conium maculatum 13cH), and Ly (treated with Lycopodium clavatum 13cH). The treatments were performed 48 h before and 48, 96, and 144 h after infection. The medication was repertorized and prepared in 13cH, according to Brazilian Homeopathic Pharmacopoeia. The following parameters were evaluated: infectivity, prepatent period, parasitemia peak, total parasitemia, tissue tropism, inflammatory infiltrate, and survival. Statistical analysis was conduced considering 5% of significance. The prepatent period was greater in the Ly group than in the CI group (p = 0.02). The number of trypomastigotes on the 8th day after infection was lower in the Ca group than in the CI group (p < 0.05). Total parasitemia was significantly lower in the Ca, Co, and Ly groups than in the CI group. On the 12th day after infection, the Ca, Co, and Ly groups had fewer nests and amastigotes/nest in the heart than the CI group (p < 0.05). Decreases in the number of nests and amastigotes in the intestine were observed in the Ly group compared with the CI group (p < 0.05). In the liver (day 12), Ly significantly prevented the formation of inflammatory foci compared with the other groups. In skeletal muscle, Co and Ly decreased the formation of inflammatory foci compared with CI (p < 0.05). Ly afforded greater animal survival compared with CI, Ca, and Co (p < 0.05). The animals in the Co group died prematurely compared with the CI group (p = 0.03). Ly with 13cH potency had significantly more benefits in the treatment of mice infected with T. cruzi, reducing the number of blood parasites, amastigote nests in tissue, and the number of amastigotes per nest and increasing animal survival.
- 1 May 2016
- Published by Georg Thieme Verlag KG in Homeopathy
- Vol. 105 (2) , 186-193
Highly diluted medication reduces tissue parasitism and inflammation in mice infected by Trypanosoma cruzi
To evaluate the effects of Kalium causticum, Conium maculatum, and Lycopodium clavatum 13cH in mice infected by Trypanosoma cruzi. In a blind, controlled, randomized study, 102 male Swiss mice, 8 weeks old, were inoculated with 1400 trypomastigotes of the Y strain of T. cruzi and distributed into the following groups: CI (treated with 7% hydroalcoholic solution), Ca (treated with Kalium causticum 13cH), Co (treated with Conium maculatum 13cH), and Ly (treated with Lycopodium clavatum 13cH). The treatments were performed 48 h before and 48, 96, and 144 h after infection. The medication was repertorized and prepared in 13cH, according to Brazilian Homeopathic Pharmacopoeia. The following parameters were evaluated: infectivity, prepatent period, parasitemia peak, total parasitemia, tissue tropism, inflammatory infiltrate, and survival. Statistical analysis was conduced considering 5% of significance. The prepatent period was greater in the Ly group than in the CI group (p = 0.02). The number of trypomastigotes on the 8th day after infection was lower in the Ca group than in the CI group (p < 0.05). Total parasitemia was significantly lower in the Ca, Co, and Ly groups than in the CI group. On the 12th day after infection, the Ca, Co, and Ly groups had fewer nests and amastigotes/nest in the heart than the CI group (p < 0.05). Decreases in the number of nests and amastigotes in the intestine were observed in the Ly group compared with the CI group (p < 0.05). In the liver (day 12), Ly significantly prevented the formation of inflammatory foci compared with the other groups. In skeletal muscle, Co and Ly decreased the formation of inflammatory foci compared with CI (p < 0.05). Ly afforded greater animal survival compared with CI, Ca, and Co (p < 0.05). The animals in the Co group died prematurely compared with the CI group (p = 0.03). Ly with 13cH potency had significantly more benefits in the treatment of mice infected with T. cruzi, reducing the number of blood parasites, amastigote nests in tissue, and the number of amastigotes per nest and increasing animal survival.
- Open Access
- 23 September 2011
- Published by International Journal of High Dilution Research - IJHDR in International Journal of High Dilution Research - ISSN 1982-6206
- Vol. 10 (36) , 134-137
Biotherapic T. cruzi 17DH when continuously used clinically improves mice infected with T. cruzi.
Introduction: In Trypanosoma cruzi infection, the pathogenesis is the result of a rupture in the host - parasite relationship [1]. This rupture is related to the imbalance of the vital force of the host, expressed through signs and symptoms, defined by Hahnemann (1995)[2] as being the source of the disease. There is no research in the literature about the clinical evolution of mice experimentally infected with T. cruzi and treated in different ways using biotherapic. Therefore, this is an area to be studied in the future. Aim: To evaluate the effect of different ways of treatment using biotherapic T. cruzi 17 DH on clinical evolution of mice experimentally infected with T. cruzi. Materials and methods: A blind randomized controlled trial was performed, using 30 swiss male mice, aged 28 days, divided into groups according to the treatment: CONTROL - animals treated with 7% water-alcohol solution diluted in water given ad libitum in an amber bottle; GAVAGE – animals treated with medication highly diluted T. cruzi 17 DH from 4th to 9th day of infection by gavage; WATER -animals treated with highly diluted T. cruzi 17 DH in water ad libitum offered in an amber bottle until the end of the study period. The groups were infected with the Y strain of T. cruzi, intraperitoneal, 1400 blood trypomastigotes. The medicine was handled according to the Brazilian Homeopathic Pharmacopoeia [3] with microbiological test according to RDC n° 67 and in vivo biological risk. Parasitemic curve was determined by daily counting of the parasites [4]. Were measured temperature, weight, intake of water and feed, the ruffle fur and survival of mice. Statistical analysis was performed using the tests Fisher Exact and Log-Rank, with a significance of 5%. The experiment was approved under the protocol n° 030/2008 - Ethics in Animal Experimentation of the Universidade Estadual de Maringá. Results: The mice under different treatment ways using biotherapic T. cruzi 17DH showed differences in the clinical evolution. The treatment using biotherapic diluted in water initially shows hypothermia, with subsequent recovery of normal temperature (p=0.05) (Fig1). The weight curve shows a better evolution in mice treated with water compared to control groups (p=0.055) and the groups treated by gavage (p=0.0064). Feed and water intake did not differ among the groups. While the mice that were treated with biotherapic diluted in water showed a slight level of ruffled fur, the mice in control groups and the ones treated by gavage showed a more intense level of ruffled fur (p=0.00001). The difference in the evolution of mortality among the groups was significant (p=0.034), while in the group treated with biotherapic diluted with water, the mortality rate started later, reaching the maximum of 90%. This group showed a better clinical result, expressed by the smaller extent of ruffled fur, a better evolution of the temperature curve and higher gain of weight. This is an important result because the Y strain of T. cruzi has a mortality rate of 100% in mice, showing once again the good performance of biotherapic in this model of infection. Conclusion: The use of biotherapic T. cruzi 17DH for a long period causes clinical improvement of the infected mice with Trypanosoma cruzi. The clinical use of these results in human beings should consider the allometric medicine dosage which takes into account the metabolic rate of each organism.
- 23 September 2011
- Published by International Journal of High Dilution Research - IJHDR in International Journal of High Dilution Research - ISSN 1982-6206
- Vol. 10 (36) , 134-137
Open AccessBiotherapic T. cruzi 17DH when continuously used clinically improves mice infected with T. cruzi.
Introduction: In Trypanosoma cruzi infection, the pathogenesis is the result of a rupture in the host - parasite relationship [1]. This rupture is related to the imbalance of the vital force of the host, expressed through signs and symptoms, defined by Hahnemann (1995)[2] as being the source of the disease. There is no research in the literature about the clinical evolution of mice experimentally infected with T. cruzi and treated in different ways using biotherapic. Therefore, this is an area to be studied in the future. Aim: To evaluate the effect of different ways of treatment using biotherapic T. cruzi 17 DH on clinical evolution of mice experimentally infected with T. cruzi. Materials and methods: A blind randomized controlled trial was performed, using 30 swiss male mice, aged 28 days, divided into groups according to the treatment: CONTROL - animals treated with 7% water-alcohol solution diluted in water given ad libitum in an amber bottle; GAVAGE – animals treated with medication highly diluted T. cruzi 17 DH from 4th to 9th day of infection by gavage; WATER -animals treated with highly diluted T. cruzi 17 DH in water ad libitum offered in an amber bottle until the end of the study period. The groups were infected with the Y strain of T. cruzi, intraperitoneal, 1400 blood trypomastigotes. The medicine was handled according to the Brazilian Homeopathic Pharmacopoeia [3] with microbiological test according to RDC n° 67 and in vivo biological risk. Parasitemic curve was determined by daily counting of the parasites [4]. Were measured temperature, weight, intake of water and feed, the ruffle fur and survival of mice. Statistical analysis was performed using the tests Fisher Exact and Log-Rank, with a significance of 5%. The experiment was approved under the protocol n° 030/2008 - Ethics in Animal Experimentation of the Universidade Estadual de Maringá. Results: The mice under different treatment ways using biotherapic T. cruzi 17DH showed differences in the clinical evolution. The treatment using biotherapic diluted in water initially shows hypothermia, with subsequent recovery of normal temperature (p=0.05) (Fig1). The weight curve shows a better evolution in mice treated with water compared to control groups (p=0.055) and the groups treated by gavage (p=0.0064). Feed and water intake did not differ among the groups. While the mice that were treated with biotherapic diluted in water showed a slight level of ruffled fur, the mice in control groups and the ones treated by gavage showed a more intense level of ruffled fur (p=0.00001). The difference in the evolution of mortality among the groups was significant (p=0.034), while in the group treated with biotherapic diluted with water, the mortality rate started later, reaching the maximum of 90%. This group showed a better clinical result, expressed by the smaller extent of ruffled fur, a better evolution of the temperature curve and higher gain of weight. This is an important result because the Y strain of T. cruzi has a mortality rate of 100% in mice, showing once again the good performance of biotherapic in this model of infection. Conclusion: The use of biotherapic T. cruzi 17DH for a long period causes clinical improvement of the infected mice with Trypanosoma cruzi. The clinical use of these results in human beings should consider the allometric medicine dosage which takes into account the metabolic rate of each organism.